Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Feasibility of a Shigella Sonnei 53G Controlled Human Infection Model in Kenyan Adults
NCT05959616Phase 1Recruiting
- Sponsor
- University of Oxford
- Start
- Jan 2025
- Primary completion
- Apr 2026
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Shigella sonnei strain 53G in shigellosis (6 arms), sponsored by University of Oxford. Primary endpoints: Number of volunteers with solicited adverse events at 11 days and Number of volunteers with an attack rate of ≥60% at 11 days. Started Jan 2025; status: recruiting.
02
Drugs
Shigella sonnei strain 53G
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT05959616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959616.